LAVA Therapeutics (NASDAQ: LVTX) has announced significant developments in Q2 2025, headlined by a definitive agreement to be acquired by XOMA Royalty Corporation. The acquisition terms include $1.16-$1.24 per share in cash, plus contingent value rights tied to LAVA's partnered and unpartnered programs, with closing expected in Q4 2025.
The company reported Q2 2025 financial results with cash position of $56.2 million as of June 30, 2025, down from $76.6 million at year-end 2024. Net loss increased to $8.6 million ($0.32 per share) compared to $8.3 million ($0.31 per share) in Q2 2024. Additionally, LAVA announced the discontinuation of its LAVA-1266 program for acute myeloid leukemia and myelodysplastic syndrome.
Two partnered programs continue to progress: J&J's JNJ-89853413 in Phase 1 trials for AML/MDS, and Pfizer's PF08046052 for advanced solid tumors.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.